TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

Naseema Gangat; Momna Warraich; Sudhesh Kumar; Mahnoor Fatima; Kristen McCullough; Kebede H. Begna; Aref Al-Kali; Mrinal M. Patnaik; William J. Hogan; Abhishek Mangaonkar; Antoine N. Saliba; Mehrdad Hefazi Torghabeh; Hassan Alkhateeb; Mithun V. Shah; James M. Foran; Talha Badar; Jeanne M. Palmer; Cecilia Arana Yi; Animesh Pardanani; Ayalew Tefferi

doi:10.1002/ajh.70248

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

Naseema Gangat
, Momna Warraich
, Sudhesh Kumar
, Mahnoor Fatima
, Kristen McCullough
, Kebede H. Begna
, Aref Al-Kali
, Mrinal M. Patnaik
, William J. Hogan
, Abhishek Mangaonkar
, Antoine N. Saliba
, Mehrdad Hefazi Torghabeh
, Hassan Alkhateeb
, Mithun V. Shah
, James M. Foran
, Talha Badar
, Jeanne M. Palmer
, Cecilia Arana Yi
, Animesh Pardanani
, Ayalew Tefferi

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	866-871
Number of pages	6
Journal	American journal of hematology
Volume	101
Issue number	4
DOIs	https://doi.org/10.1002/ajh.70248
State	Published - Apr 2026

Keywords

JAK2
hypomethylating
myelofibrosis
polycythemia
thrombocythemia

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.70248

Cite this

Gangat, N., Warraich, M., Kumar, S., Fatima, M., McCullough, K., Begna, K. H., Al-Kali, A., Patnaik, M. M., Hogan, W. J., Mangaonkar, A., Saliba, A. N., Torghabeh, M. H., Alkhateeb, H., Shah, M. V., Foran, J. M., Badar, T., Palmer, J. M., Yi, C. A., Pardanani, A., & Tefferi, A. (2026). TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent. American journal of hematology, 101(4), 866-871. https://doi.org/10.1002/ajh.70248

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent. / Gangat, Naseema; Warraich, Momna; Kumar, Sudhesh et al.
In: American journal of hematology, Vol. 101, No. 4, 04.2026, p. 866-871.

Research output: Contribution to journal › Letter › peer-review

Gangat, N, Warraich, M, Kumar, S, Fatima, M, McCullough, K, Begna, KH, Al-Kali, A, Patnaik, MM , Hogan, WJ, Mangaonkar, A, Saliba, AN, Torghabeh, MH, Alkhateeb, H, Shah, MV, Foran, JM, Badar, T, Palmer, JM, Yi, CA, Pardanani, A & Tefferi, A 2026, 'TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent', American journal of hematology, vol. 101, no. 4, pp. 866-871. https://doi.org/10.1002/ajh.70248

@article{557f693596ce4f1884ddbfc594b8e24c,

title = "TP53 Mutations and Circulating Blasts ≥ 20\% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent",

keywords = "JAK2, hypomethylating, myelofibrosis, polycythemia, thrombocythemia",

author = "Naseema Gangat and Momna Warraich and Sudhesh Kumar and Mahnoor Fatima and Kristen McCullough and Begna, \{Kebede H.\} and Aref Al-Kali and Patnaik, \{Mrinal M.\} and Hogan, \{William J.\} and Abhishek Mangaonkar and Saliba, \{Antoine N.\} and Torghabeh, \{Mehrdad Hefazi\} and Hassan Alkhateeb and Shah, \{Mithun V.\} and Foran, \{James M.\} and Talha Badar and Palmer, \{Jeanne M.\} and Yi, \{Cecilia Arana\} and Animesh Pardanani and Ayalew Tefferi",

year = "2026",

month = apr,

doi = "10.1002/ajh.70248",

language = "English (US)",

volume = "101",

pages = "866--871",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

AU - Gangat, Naseema

AU - Warraich, Momna

AU - Kumar, Sudhesh

AU - Fatima, Mahnoor

AU - McCullough, Kristen

AU - Begna, Kebede H.

AU - Al-Kali, Aref

AU - Patnaik, Mrinal M.

AU - Hogan, William J.

AU - Mangaonkar, Abhishek

AU - Saliba, Antoine N.

AU - Torghabeh, Mehrdad Hefazi

AU - Alkhateeb, Hassan

AU - Shah, Mithun V.

AU - Foran, James M.

AU - Badar, Talha

AU - Palmer, Jeanne M.

AU - Yi, Cecilia Arana

AU - Pardanani, Animesh

AU - Tefferi, Ayalew

PY - 2026/4

Y1 - 2026/4

KW - JAK2

KW - hypomethylating

KW - myelofibrosis

KW - polycythemia

KW - thrombocythemia

UR - https://www.scopus.com/pages/publications/105030551121

UR - https://www.scopus.com/pages/publications/105030551121#tab=citedBy

U2 - 10.1002/ajh.70248

DO - 10.1002/ajh.70248

M3 - Letter

C2 - 41708842

AN - SCOPUS:105030551121

SN - 0361-8609

VL - 101

SP - 866

EP - 871

JO - American journal of hematology

JF - American journal of hematology

IS - 4

ER -

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this